BioPharmSignal logoBioPharmSignal

Biotech News

CVRx to Participate in Upcoming Investor Conferences

CVRx (CVRX)CVRxCommercial

MINNEAPOLIS, Nov. 02, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management

Related news

CVRXCVRx2026-09-21 20:08 EST

CVRx Appoints John Landry as Chief Financial Officer

PAVMPAVmed2026-11-04 13:55 EST

Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

PAVMPAVmed2026-11-05 13:25 EST

Lucid Diagnostics Recognized as a GenomeWeb Best Place to Work for Second Consecutive Year

RYTMRhythm Pharmaceuticals2026-11-04 13:00 EST

Rhythm Pharmaceuticals Announces NICE Guidance for IMCIVREE® (Setmelanotide) Updated to Include Adults Living with Bardet-Biedl Syndrome

RXSTRxSight2026-10-19 13:00 EST

RxSight Appoints Eye Care Industry Leaders to Drive Commercial Transformation

RYTMRhythm Pharmaceuticals2026-10-13 23:30 EST

Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity

ADPTAdaptive Biotechnologies2026-09-25 12:03 EST

Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure

CVRXCVRx2026-11-05 21:05 EST

CVRx Reports Third Quarter 2026 Financial and Operating Results

MLYSMineralys Therapeutics2026-10-19 20:05 EST

Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats

IARTIntegra LifeSciences2026-10-02 12:00 EST

Integra LifeSciences Announces Launch of $600 Million Senior Secured Term Loan B

View all latest news

CVRx

Cardiovascular Neuromodulation CVRx is a commercial-stage medical-device company focused on neuromodulation therapies for cardiovascular disease. Its technology electrically activates the body's baroreflex to influence autonomic pathways involved in heart-failure progression. Barostim Platform Barostim is the company's implantable...

Recent company news

CVRXCVRx2026-11-05 21:05 EST

CVRx Reports Third Quarter 2026 Financial and Operating Results

CVRXCVRx2026-11-02 21:02 EST

CVRx to Participate in Upcoming Investor Conferences

CVRXCVRx2026-10-22 20:30 EST

CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026

CVRXCVRx2026-09-29 20:30 EST

CVRx Announces Late-Breaking Data and New Clinical Evidence on Barostim at the HFSA Annual Scientific Meeting 2026

CVRXCVRx2026-09-21 20:08 EST

CVRx Appoints John Landry as Chief Financial Officer

Stock data

Close
1.47 USD
Market cap
144.09M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States